GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Pear Therapeutics Inc (OTCPK:PEARQ) » Definitions » Cash Ratio

Pear Therapeutics (Pear Therapeutics) Cash Ratio : 1.20 (As of Dec. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Pear Therapeutics Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Pear Therapeutics's Cash Ratio for the quarter that ended in Dec. 2022 was 1.20.

Pear Therapeutics has a Cash Ratio of 1.20. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Pear Therapeutics's Cash Ratio or its related term are showing as below:

PEARQ's Cash Ratio is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 0.5
* Ranked among companies with meaningful Cash Ratio only.

Pear Therapeutics Cash Ratio Historical Data

The historical data trend for Pear Therapeutics's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pear Therapeutics Cash Ratio Chart

Pear Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Cash Ratio
6.11 3.06 3.70 1.20

Pear Therapeutics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.70 2.96 2.28 1.74 1.20

Competitive Comparison of Pear Therapeutics's Cash Ratio

For the Health Information Services subindustry, Pear Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pear Therapeutics's Cash Ratio Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Pear Therapeutics's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Pear Therapeutics's Cash Ratio falls into.



Pear Therapeutics Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Pear Therapeutics's Cash Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash Ratio (A: Dec. 2022 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=59.272/49.442
=1.20

Pear Therapeutics's Cash Ratio for the quarter that ended in Dec. 2022 is calculated as:

Cash Ratio (Q: Dec. 2022 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=59.272/49.442
=1.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pear Therapeutics  (OTCPK:PEARQ) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Pear Therapeutics Cash Ratio Related Terms

Thank you for viewing the detailed overview of Pear Therapeutics's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Pear Therapeutics (Pear Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
200 State Street, 13th Floor, Boston, MA, USA, 02109
Pear Therapeutics Inc is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDTs), which use software to treat diseases directly. The company's vision is to advance healthcare through the widespread use of PDTs and to be the one-stop shop for PDTs offered by Pear and other organizations that may choose to make their products available to patients, providers, and payors via its commercial platform, known as PearConnect. It features four distinct system components, consisting of PDTs for patient use, the PearMD Clinician Dashboard, an end-to-end patient service center, and a data analytics system configured to aggregate patient engagement, adherence, and clinical outcome data.
Executives
5am Partners Iv, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Erin K. Brenner officer: Chief Product Dev. Officer C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Julia Strandberg officer: Chief Commercial Officer C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Ronan O'brien officer: General Counsel & Secretary C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Mccann Corey director, officer: President and CEO C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Yuri Maricich officer: Chief Medical Officer C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Ellen Snow officer: Chief Accounting Officer C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Christopherd T Guiffre officer: CFO, COO, Treas., & Asst. Sec. 65 HAYDEN AVE, LEXINGTON MA 02421
Katherine Jeffery officer: Chief People Officer C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Paul Mango director C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Timothy A Wicks director C/O PRECISION CASTPARTS CORP., 4650 SW MACADAM AVENUE, SUITE 400, PORTLAND OR 97239
Shivakumar Rajaraman director 6260 LOOKOUT ROAD, BOULDER CO 80301
Klp Spac 1 Llc 10 percent owner 195 CHURCH STREET , 15TH FLOOR, NEW HAVEN CT 06510
Zack Lynch director C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Elbrus Investments Pte. Ltd. 10 percent owner 60B ORCHARD ROAD #06-18, THE ATRIUM@ORCHARD, SINGAPORE U0 238891

Pear Therapeutics (Pear Therapeutics) Headlines

From GuruFocus

Pear Therapeutics Announces Three New Board Members

By Business Wire Business Wire 06-15-2022

Pear Therapeutics Announces Process Exploring Strategic Alternatives

By Business Wire Business Wire 03-17-2023